0000000000064034

AUTHOR

Luzalba Sanoja-flores

showing 2 related works from this author

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

2020

The reason why a few myeloma cells egress from the bone marrow (BM) into peripheral blood (PB) remains unknown. Here, we investigated molecular hallmarks of circulating tumor cells (CTCs) to identify the events leading to myeloma trafficking into the bloodstream. After using next-generation flow to isolate matched CTCs and BM tumor cells from 32 patients, we found high correlation in gene expression at single-cell and bulk levels (r ≥ 0.94, P = 10−16), with only 55 genes differentially expressed between CTCs and BM tumor cells. CTCs overexpressed genes involved in inflammation, hypoxia, or epithelial–mesenchymal transition, whereas genes related with proliferation were downregulated in CTCs…

0301 basic medicineCancer ResearchEpithelial-Mesenchymal TransitionTranscription GeneticGene ExpressionBiologycirculating tumor cell03 medical and health sciences0302 clinical medicineCirculating tumor cellBone MarrowCell MovementCancer stem cellCell Line TumorTumor MicroenvironmentmedicineHumansHypoxiaMultiple myelomaCell ProliferationInflammationGene knockdownliquid biopsyCD44CENPFHematologyNeoplastic Cells CirculatingPrognosismedicine.disease3. Good healthmultiple myeloma030104 developmental biologymedicine.anatomical_structureOncologyCell culture030220 oncology & carcinogenesisNeoplastic Stem CellsCancer researchbiology.proteinBone marrow
researchProduct

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.

2020

[Purpose] Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG).

OncologyMaleCancer Researchmedicine.medical_specialtyNeoplasm ResidualDiseaseResidualTHERAPYDexamethasoneFlow cytometryBortezomib03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMeaning (existential)Longitudinal StudiesLenalidomideMultiple myeloma030304 developmental biologyCONSOLIDATIONRandomized Controlled Trials as Topic0303 health sciencesCOMPLETE RESPONSEmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseFlow Cytometry3. Good healthClinical trialPROGNOSTIC VALUEbody regionsMRDOncologyClinical Trials Phase III as Topic030220 oncology & carcinogenesisFemaleSTEM-CELL TRANSPLANTbusinessMultiple MyelomaDARATUMUMABJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct